Profile data is unavailable for this security.
About the company
BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.
- Revenue in USD (TTM)2.47bn
- Net income in USD205.46m
- Incorporated1996
- Employees3.40k
- LocationBiomarin Pharmaceutical Inc770 Lindaro StreetSAN RAFAEL 94901United StatesUSA
- Phone+1 (415) 505-6700
- Fax+1 (415) 382-7889
- Websitehttps://www.biomarin.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Intra-Cellular Therapies Inc | 513.93m | -110.87m | 8.08bn | 610.00 | -- | 12.44 | -- | 15.72 | -1.15 | -1.15 | 5.34 | 6.15 | 0.6996 | 1.67 | 4.83 | 842,508.20 | -15.09 | -38.27 | -17.67 | -42.77 | 92.82 | -- | -21.57 | -128.42 | 5.00 | -- | 0.00 | -- | 85.51 | -- | 45.49 | -- | -7.22 | -- |
Roivant Sciences Ltd | 124.80m | 4.35bn | 8.31bn | 845.00 | 2.22 | 1.52 | 1.95 | 66.59 | 5.07 | 5.07 | 0.1571 | 7.40 | 0.026 | 0.8187 | 2.97 | 147,686.40 | 88.04 | -- | 103.92 | -- | 87.53 | -- | 3,390.53 | -- | 25.10 | -- | 0.0642 | -- | 103.65 | -- | 487.06 | -- | -- | -- |
Catalent Inc | 4.14bn | -1.18bn | 10.51bn | 17.80k | -- | 2.90 | -- | 2.54 | -6.48 | -6.48 | 22.69 | 20.06 | 0.3993 | 4.36 | 2.87 | 232,303.40 | -11.36 | 2.88 | -12.91 | 3.26 | 18.96 | 31.03 | -28.44 | 6.35 | 1.74 | 0.0154 | 0.5797 | 0.00 | -11.22 | 11.59 | -153.00 | -- | 26.69 | -- |
Viatris Inc | 15.36bn | -56.10m | 14.10bn | 38.00k | -- | 0.7042 | 5.33 | 0.9177 | -0.0499 | -0.0499 | 12.75 | 16.81 | 0.3179 | 2.33 | 5.29 | 404,242.10 | -0.1161 | 0.0887 | -0.1356 | 0.1061 | 43.26 | 40.29 | -0.3652 | 0.2891 | 1.17 | 2.63 | 0.473 | 560.11 | -5.14 | 6.17 | -97.37 | -30.53 | -16.88 | -- |
Incyte Corp | 3.77bn | 745.44m | 14.66bn | 2.52k | 19.83 | 2.72 | 17.65 | 3.89 | 3.29 | 3.29 | 16.64 | 24.02 | 0.5827 | 4.52 | 5.50 | 1,492,815.00 | 11.53 | 9.07 | 14.16 | 11.02 | 93.73 | 94.97 | 19.78 | 13.68 | 3.43 | -- | 0.006 | 0.00 | 8.87 | 14.45 | 75.42 | 40.41 | -15.06 | -- |
Biomarin Pharmaceutical Inc | 2.47bn | 205.46m | 16.08bn | 3.40k | 79.10 | 3.17 | 51.73 | 6.50 | 1.07 | 1.07 | 12.77 | 26.74 | 0.3715 | 0.4993 | 4.00 | 726,740.40 | 3.09 | 0.7116 | 3.54 | 0.8079 | 79.22 | 76.30 | 8.31 | 2.05 | 1.70 | -- | 0.1766 | 0.00 | 15.42 | 10.16 | 36.51 | -- | -5.74 | -- |
Royalty Pharma plc | 2.24bn | 798.86m | 16.79bn | 89.00 | 15.76 | 1.95 | 14.10 | 7.50 | 1.78 | 1.78 | 3.73 | 14.41 | 0.1348 | -- | 73.80 | 25,152,370.00 | 7.15 | 9.57 | 9.60 | 12.42 | -- | -- | 53.01 | 67.80 | -- | -- | 0.3836 | 23.47 | 5.24 | 5.58 | 2,549.50 | -3.80 | 50.99 | -- |
Holder | Shares | % Held |
---|---|---|
The Vanguard Group, Inc.as of 28 Jun 2024 | 18.99m | 10.00% |
PRIMECAP Management Co.as of 31 Mar 2024 | 18.71m | 9.86% |
Dodge & Coxas of 31 Mar 2024 | 13.99m | 7.37% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 9.92m | 5.22% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 6.90m | 3.63% |
Capital Research & Management Co. (Global Investors)as of 31 Mar 2024 | 6.52m | 3.43% |
Viking Global Investors LPas of 31 Mar 2024 | 6.42m | 3.38% |
Barclays Bank Plc (Private Banking)as of 31 Mar 2024 | 5.15m | 2.71% |
UBS Securities LLCas of 31 Mar 2024 | 4.96m | 2.61% |
Columbia Management Investment Advisers LLCas of 31 Mar 2024 | 4.61m | 2.43% |